Strategies for tumor elimination by cytotoxic T lymphocytes

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 47-54

  Sherman, Linda A ^a   Theobald, Matthias ^b   Morgan, David ^a   Hernandez, Javier ^a   Bacik, Igor ^c   Yewdell, Jonathan ^c   Bennink, Jack ^c   Biggs, Judith ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cytotoxic T lymphocytes; HLA transgenic mice; p53; Tolerance; Tumor antigens

Indexed keywords

HEMAGGLUTININ; PROTEIN P53; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; ANIMAL; ARTICLE; HUMAN; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNE TOLERANCE; MICE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030721437     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X-Q., South wood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S., Recognition of multiple epitopes in the human melanoma antigen gp 100 associated with in vivo tumor regression, J. Immunol., 154, 3961, 1995.
2. Bakker, A., Schreurs, M., Tafazzul, G., De Boer, A., Kawakami, Y., Adema, G., Figdor, C., Identification of a novel peptide derived from the melanocyte-specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line, Int. J. Cancer, 62, 97, 1995.
3. Cox, A. L., Skipper, J., Cehn, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunl, D. F., and Slingluff, C. L., Identifi- cation of a peptide recognized by five melanomaspecific human cytotoxic T cell lines, Science, 264, 716, 1994.
4. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med., 178, 489, 1993.
5. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer Zum Buschenfelde, K-H., and Boon, T., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes, Eur. J. Immunol., 24, 759, 1994.
6. Robbins, P. F., El-Gamil, M., Kawakami, Y., Stevens, E., Yannelli, J., and Rosenberg, S. A., Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy, Cancer Res., 54, 3124, 1994.
7. Robbins, P. F., El-Gamil, M., Li, Y. F., Topalian, S. L., Rivoltini, L., Sakaguchi, K., Appella, E., Kawakami, Y., and Rosenberg, S. A., Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes, J. Immunol., 154, 5944, 1995.
8. Noguchi, Y., Chen, Y. T., and Old, L. J., A mouse mutant p53 product recognized by CD4+ and CD8+ T cells, Proc. Natl. Acad. Sci. U.S.A., 91, 3171, 1994.
9. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B., Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines, J. Exp. Med., 183, 1357, 1996.
10. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A. J., p53 as target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge, Proc. Natl Acad. Sci. U.S.A., 93, 4781, 1996.
11. Houbiers, J. G. A., Nijman, H. W., Burg, S. H. v. d., Drijfhout, J. W., Kenemans, P., Velde, C. J. v. d., Brand, A., Momburg, F., Kast, W. M., and Melief, C., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53, Eur. J. Immunol., 23, 2072, 1993.
12. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A., Targeting p53 as a general tumor antigen, Proc. Natl. Acad. Sci. U.S.A., 92, 11993, 1995.
13. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, J. M., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J., HER 2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer, Cancer Res., 54, 3387, 1994.
14. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A., In vitro generation of human cytolytic T-cells specific for peptides derived from the Her-2/neu protooncogene protein, Cancer Res., 54, 1071, 1994.
15. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton, J. T., and O'Brian, C. A., Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene, Cell. Immunol., 151, 225, 1993.
16. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G., Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, J. Exp. Med., 181, 2109, 1995.
17. Whiteside, T. L. and Parmiani, G., Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use, Cancer Immunol. Immunother., 39, 15, 1994.
18. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A., and Sherman, L. A., Identification of Her-2/New CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8., Human Immunol., 52, 109, 1997.
19. Levine, A. J., Momand, J., and Finlay, C. A., The p53 tumor suppressor gene, Nature, 351, 453, 1991.
20. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C., p53 mutations in human cancers, Science, 253, 49, 1991.
21. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chestnut, R. W., Analysis of the HLA-restricted influenza-specific CTL response in transgenic mice carrying a chimeric human-mouse class I MHC molecule, J. Exp. Med., 173, 1007, 1991.
22. Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., and Sherman, L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes, J. Exp. Med., 185, 833, 1997.
23. Lo, D., Freedman, J., Hesse, J., Palmiter, R. D., Brinster, R. L., and Sherman, L. A., Peripheral tolerance to an islet cell specific hemagglutinin transgene affects both CD4+ and CD8+ T cells, Eur. J. Immunol., 22, 1013, 1992.
24. Morgan, D. J., Kreuwel, H. T. C., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A., The effect of tolerance on rejection of tumor cells expressing self-antigen, submitted, 1997.
25. Huang, A. Y. C., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I., Does B7-1 expression confer antigenpresenting cell capacity to tumors in vivo, J. Exp. Med., 183,769, 1996.
26. Irwin, M. J., Health, W. R., and Sherman, L. A., Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the zenogenic response, J. Exp. Med., 170, 1091, 1989.
27. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., Ruppert, J., Sidney, J., Guercio, M.F. D., Southwood, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Chisari, F. V., The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes, J. Immunol., 153, 5586, 1994.
28. Anton, L. C., Yewdell, J. W., and Bennink, J. R., MHC class I-associated peptides produced from en- dogenous gene products with vastly different efficiencies, J. Immunol., 158, 2535, 1997.